Profile data is unavailable for this security.
About the company
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
- Revenue in USD (TTM)44.25bn
- Net income in USD13.07bn
- Incorporated1994
- Employees100.41k
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Synthorx Inc | 4.16% | 2.45bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | 5.40bn | 2.08bn | 68.21bn | 3.00k | 33.10 | 9.06 | 31.20 | 12.62 | 7.91 | 7.91 | 20.59 | 28.91 | 0.6264 | 3.67 | 8.60 | 1,800,895.00 | 24.13 | 5.48 | 29.32 | 6.99 | 87.71 | 87.50 | 38.51 | 9.03 | 3.60 | -- | 0.0649 | 0.00 | 36.59 | 48.30 | 119.39 | -- | 8.06 | -- |
| Zoetis Inc | 6.34bn | 1.62bn | 74.56bn | 10.60k | 46.42 | 25.00 | 36.32 | 11.76 | 3.38 | 3.38 | 13.26 | 6.28 | 0.5271 | 1.28 | 6.41 | 598,113.20 | 13.44 | 11.62 | 15.27 | 13.71 | 69.95 | 66.83 | 25.49 | 18.90 | 2.60 | 10.07 | 0.7204 | 22.90 | 7.47 | 5.52 | 8.46 | 20.80 | 20.64 | 17.02 |
| Gilead Sciences, Inc. | 22.17bn | -257.00m | 85.38bn | 11.80k | -- | 4.74 | 76.99 | 3.85 | -0.2426 | -0.2426 | 17.51 | 14.38 | 0.3722 | 4.91 | 6.73 | 1,879,153.00 | -0.4818 | 18.07 | -0.5776 | 21.88 | 78.57 | 83.42 | -1.29 | 39.31 | 2.23 | -18.13 | 0.5705 | 25.34 | 1.46 | -2.04 | -1.34 | -14.95 | 8.17 | -- |
| Sanofi SA (ADR) | 44.25bn | 13.07bn | 129.47bn | 100.41k | 9.78 | 1.71 | 8.76 | 2.93 | 5.19 | 5.15 | 17.62 | 29.64 | 0.333 | 1.40 | 5.22 | 440,664.80 | 9.44 | 3.69 | 11.36 | 4.39 | 67.81 | 68.37 | 28.34 | 10.78 | 1.38 | 35.08 | 0.2821 | -- | 5.48 | 3.30 | -32.69 | -7.41 | 4.56 | -- |
| Amgen, Inc. | 24.30bn | 7.30bn | 137.43bn | 23.40k | 19.17 | 12.91 | 13.30 | 5.66 | 12.24 | 12.24 | 40.76 | 18.18 | 0.3907 | 1.51 | 5.30 | 1,038,504.00 | 11.74 | 10.83 | 14.14 | 12.67 | 78.23 | 81.75 | 30.04 | 34.01 | 1.81 | 10.32 | 0.7625 | 41.54 | -1.62 | 3.09 | -6.58 | 8.74 | -9.23 | 18.91 |
| Bristol-Myers Squibb Co | 34.86bn | -563.00m | 142.29bn | 30.00k | -- | 2.90 | 23.66 | 4.08 | -0.1033 | -0.1033 | 17.27 | 21.78 | 0.3805 | 5.68 | 6.22 | 1,162,067.00 | -0.5894 | 8.56 | -0.7203 | 11.21 | 69.94 | 72.59 | -1.55 | 17.51 | 1.36 | 8.69 | 0.487 | 72.45 | 15.89 | 10.49 | -30.89 | 11.41 | 9.71 | 2.64 |
| Eli Lilly And Co | 22.95bn | 5.62bn | 144.07bn | 33.63k | 24.51 | 35.20 | 21.05 | 6.28 | 6.15 | 6.15 | 25.10 | 4.28 | 0.5692 | 1.51 | 4.41 | 682,521.90 | 13.93 | 8.76 | 19.88 | 12.28 | 78.67 | 76.62 | 24.48 | 16.77 | 0.9399 | 22.64 | 0.7926 | 64.42 | 3.84 | 2.62 | 39.45 | 14.17 | -2.87 | 5.65 |
| AbbVie Inc | 36.23bn | 6.91bn | 163.55bn | 47.00k | 20.39 | 11.12 | 16.14 | 4.51 | 4.55 | 4.55 | 23.28 | 8.34 | 0.3506 | 3.25 | 5.24 | 1,207,567.00 | 6.73 | 9.90 | 8.43 | 12.72 | 73.31 | 77.14 | 19.20 | 21.34 | 0.6978 | 6.35 | 0.8558 | 79.29 | 1.57 | 10.76 | 36.55 | 34.62 | -2.04 | 20.86 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Mar 2020 | 48.26m | 1.92% |
| Fisher Asset Management LLCas of 30 Jun 2020 | 18.16m | 0.72% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2020 | 14.22m | 0.57% |
| BlackRock Investment Management LLCas of 31 Mar 2020 | 7.98m | 0.32% |
| Invesco Advisers, Inc.as of 31 Mar 2020 | 6.96m | 0.28% |
| Managed Account Advisors LLCas of 31 Mar 2020 | 5.34m | 0.21% |
| Morgan Stanley & Co. International Plcas of 31 Mar 2020 | 3.81m | 0.15% |
| Hotchkis & Wiley Capital Management LLCas of 31 Mar 2020 | 3.35m | 0.13% |
| Lazard Asset Management LLCas of 31 Mar 2020 | 3.30m | 0.13% |
| Macquarie Investment Management Business Trustas of 31 Mar 2020 | 3.10m | 0.12% |
